Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003
July 15, 2015 at 08:32 AM EDT
Argos Therapeutics Inc. (Nasdaq: ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully ...